Literature DB >> 19047598

Treatment of community-acquired pneumonia.

Donald E Low.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19047598      PMCID： PMC2585140          DOI： 10.1503/cmaj.081593

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 2.  Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance.

Authors:  Joshua P Metlay; Daniel E Singer
Journal:  Clin Microbiol Infect       Date:  2002       Impact factor: 8.067

3.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

4.  Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.

Authors:  N Daneman; A McGeer; K Green; D E Low
Journal:  Clin Infect Dis       Date:  2006-07-07       Impact factor: 9.079

5.  Predicting antimicrobial resistance in invasive pneumococcal infections.

Authors:  Otto G Vanderkooi; Donald E Low; Karen Green; Jeff E Powis; Allison McGeer
Journal:  Clin Infect Dis       Date:  2005-03-31       Impact factor: 9.079

6.  A worldwide perspective of atypical pathogens in community-acquired pneumonia.

Authors:  Forest W Arnold; James T Summersgill; Andrew S Lajoie; Paula Peyrani; Thomas J Marrie; Paolo Rossi; Francesco Blasi; Patricia Fernandez; Thomas M File; Jordi Rello; Rosario Menendez; Lucia Marzoratti; Carlos M Luna; Julio A Ramirez
Journal:  Am J Respir Crit Care Med       Date:  2007-03-01       Impact factor: 21.405

Review 7.  How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.

Authors:  J J Oosterheert; M J M Bonten; E Hak; M M E Schneider; I M Hoepelman
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

8.  Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Konstantinos Z Vardakas; Ilias I Siempos; Alexandros Grammatikos; Zoe Athanassa; Ioanna P Korbila; Matthew E Falagas
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

9.  At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.

Authors:  Nick Daneman; Donald E Low; Alison McGeer; Karen A Green; David N Fisman
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

10.  Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.

Authors:  K Oishi; F Sonoda; S Kobayashi; A Iwagaki; T Nagatake; K Matsushima; K Matsumoto
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441
  10 in total
  2 in total

1.  Control of Clostridium difficile-associated diarrhea by antibiotic stewardship in a small community hospital.

Authors:  Alice Schabas; David N Fisman; Richard Schabas
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.

Authors:  Takafumi Sato; Kazuhiro Tateda; Soichiro Kimura; Morihiro Iwata; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.